All News

Found 3,314 articles

• BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones

  1/10/2023

  BioAtla, Inc. announced its recent accomplishments for its clinical pipeline and provided upcoming 2023 milestones.

• EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE

  1/10/2023

  Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai has submitted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI™).

• Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

  1/10/2023

  Ajinomoto Co., Inc. ("Ajinomoto Co.") today announced a license agreement with Exelixis, Inc. ("Exelixis") to incorporate AJICAP®, Ajinomoto Co.'s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis' antibody-drug conjugate (ADC) programs.

• mRNA with Defence's Accum(TM) Program Has Been Initiated

  1/10/2023

  Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the advancement in the development of its AccumTM -mRNA vaccine program.

• Adimab Provides Year-End Update on 2022 Partnership Activities

  1/10/2023

  Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it entered into partnership agreements with 11 new companies in 2022.

• G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib

  1/9/2023

  G1 Therapeutics, Inc. (Nasdaq: GTHX) today announced the 2023 data readouts that are expected to drive its near-term and long-term indications and potential future treatment paradigms for some of the most aggressive and refractory cancers, including metastatic colorectal (mCRC), bladder or urothelial cancer (mUC), and triple negative breast cancer (TNBC).

• AmMax Bio Enters into an Exclusive Option Agreement with Evopoint Biosciences to License a Next Generation Antibody Drug Conjugate (ADC) for the Treatment of Solid Tumors

  1/9/2023

  AmMax Bio, Inc. (“AmMax”)and Evopoint Biosciences Co., Ltd (“Evopoint”) today announced that AmMax has entered into an exclusive option with Evopoint for a worldwide license, excluding Greater China, for the development and commercialization of a novel ADC for treating solid tumors.

• Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023

  1/8/2023

  Exelixis, Inc. announced its preliminary unaudited financial results for the fourth quarter and full year 2022, provided financial guidance for full year 2023, and delivered an update on its business.

• 

  Amgen Makes Early $2B Play to Boost ADC Portfolio

  1/6/2023

  In another early high-value deal, Amgen inked a licensing agreement with Synaffix for the development of next-generation antibody-drug conjugates. 

• Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 06, 2023

  1/6/2023

  Mersana Therapeutics, Inc. announced that on January 3, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 25,575 shares of its common stock and restricted stock unit awards to acquire an aggregate of 26,700 shares of its common stock, to five new employees whose employment commenced in December 2022.

• LAVA Therapeutics Announces Appointment of New Directors to the Board

  1/6/2023

  LAVA Therapeutics N.V., a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, announced the appointment of two new directors to its Board of Directors.

• Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones

  1/6/2023

  Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and announced strategic objectives and expected milestones for 2023.

• Elevation Oncology Announces Pipeline Prioritization, Realignment of Resources to Advance EO-3021 and CEO Transition

  1/6/2023

  Elevation Oncology, Inc. today announced plans to prioritize key research and development efforts to advance EO-3021, its potential best-in-class antibody-drug conjugate (ADC) designed to target Claudin18.2, and other pipeline programs including those through its existing partnership with Caris Life Sciences.

• ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023

  1/5/2023

  ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, provided a corporate update and highlighted key milestones anticipated in 2023.

• FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma

  1/5/2023

  Lantern Pharma Inc. (NASDAQ: LTRN) today announced that the U.S. Food and Drug Administration (FDA) has granted LP-284 Orphan Drug Designation (ODD) for the treatment of mantle cell lymphoma (MCL).

• Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

  1/5/2023

  Moderna, Inc. and CytomX Therapeutics, Inc. announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna's mRNA technologies and CytomX's Probody® therapeutic platform.

• Biocytogen Launches RenNano® Mouse, a Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery

  1/5/2023

  Biocytogen Pharmaceuticals Co., Ltd. officially launched its fully human heavy chain antibody platform, RenNano®. RenNano® is the third member of the RenMice™ family, joining RenMab™ and RenLite®.

• CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

  1/5/2023

  CytomX Therapeutics, Inc. and Moderna, Inc. announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna’s mRNA technologies and CytomX’s Probody® therapeutic platform.

• CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities

  1/5/2023

  CytomX Therapeutics, Inc. announced its 2023 company priorities and provided a pipeline update which included anticipated milestones for 2023, recent progress and achievements in its wholly owned and collaboration pipeline, and a data update for the Phase 2, CX-2029 cohort expansion study.

• Diaccurate receives support from Bpifrance to conduct its DIACC2020 Program on the development of new payloads for antibody-drug conjugates (ADCs)

  1/5/2023

  Diaccurate announced it received from Bpifrance a grant termed “Aide à l’Innovation” to support its DIACC2020 Program aiming to establish the preclinical proof-of-concept of its sole-in-class molecule DIACC2010 as a next-generation payload for ADCs, for the treatment of solid and hematologic tumors.